321 related articles for article (PubMed ID: 24447648)
1. D-penicillamine versus zinc sulfate as first-line therapy for Wilson's disease.
Członkowska A; Litwin T; Karliński M; Dziezyc K; Chabik G; Czerska M
Eur J Neurol; 2014 Apr; 21(4):599-606. PubMed ID: 24447648
[TBL] [Abstract][Full Text] [Related]
2. Compliant treatment with anti-copper agents prevents clinically overt Wilson's disease in pre-symptomatic patients.
Dzieżyc K; Karliński M; Litwin T; Członkowska A
Eur J Neurol; 2014 Feb; 21(2):332-7. PubMed ID: 24313946
[TBL] [Abstract][Full Text] [Related]
3. Combined sodium Dimercaptopropanesulfonate and zinc versus D-penicillamine as first-line therapy for neurological Wilson's disease.
Zhang J; Xiao L; Yang W
BMC Neurol; 2020 Jun; 20(1):255. PubMed ID: 32593295
[TBL] [Abstract][Full Text] [Related]
4. Maintenance zinc therapy after initial penicillamine chelation to treat symptomatic hepatic Wilson's disease in resource constrained setting.
Gupta P; Choksi M; Goel A; Zachariah U; Sajith KG; Ramachandran J; Chandy G; Kurian G; Rebekah G; Eapen CE
Indian J Gastroenterol; 2018 Jan; 37(1):31-38. PubMed ID: 29457214
[TBL] [Abstract][Full Text] [Related]
5. Early neurological worsening in patients with Wilson's disease.
Litwin T; Dzieżyc K; Karliński M; Chabik G; Czepiel W; Członkowska A
J Neurol Sci; 2015 Aug; 355(1-2):162-7. PubMed ID: 26071888
[TBL] [Abstract][Full Text] [Related]
6. Withdrawal of penicillamine from zinc sulphate-penicillamine maintenance therapy in Wilson's disease: promising, safe and cheap.
Sinha S; Taly AB
J Neurol Sci; 2008 Jan; 264(1-2):129-32. PubMed ID: 17765927
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of oral chelators in treatment of patients with Wilson disease.
Weiss KH; Thurik F; Gotthardt DN; Schäfer M; Teufel U; Wiegand F; Merle U; Ferenci-Foerster D; Maieron A; Stauber R; Zoller H; Schmidt HH; Reuner U; Hefter H; Trocello JM; Houwen RH; Ferenci P; Stremmel W;
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1028-35.e1-2. PubMed ID: 23542331
[TBL] [Abstract][Full Text] [Related]
8. Spatial investigation of the elemental distribution in Wilson's disease liver after d-penicillamine treatment by LA-ICP-MS.
Hachmöller O; Zibert A; Zischka H; Sperling M; Groba SR; Grünewald I; Wardelmann E; Schmidt HH; Karst U
J Trace Elem Med Biol; 2017 Dec; 44():26-31. PubMed ID: 28965585
[TBL] [Abstract][Full Text] [Related]
9. Gastropathy in patients with Wilson disease.
Antczak-Kowalska M; Członkowska A; Litwin T; Nehring P; Niewada M; Przybyłkowski A
Scand J Gastroenterol; 2020 Jan; 55(1):14-17. PubMed ID: 31865812
[No Abstract] [Full Text] [Related]
10. Wilson's disease: long-term follow-up of a cohort of 24 patients treated with D-penicillamine.
Lowette KF; Desmet K; Witters P; Laleman W; Verslype C; Nevens F; Fevery J; Cassiman DM
Eur J Gastroenterol Hepatol; 2010 May; 22(5):564-71. PubMed ID: 20042865
[TBL] [Abstract][Full Text] [Related]
11. Symptomatic copper deficiency in three Wilson's disease patients treated with zinc sulphate.
Dzieżyc K; Litwin T; Sobańska A; Członkowska A
Neurol Neurochir Pol; 2014; 48(3):214-8. PubMed ID: 24981187
[TBL] [Abstract][Full Text] [Related]
12. [Wilson's disease. Clinical presentation, treatment and evolution in 21 cases].
Bono W; Moutie O; Benomar A; Aïdi S; el Alaoui-Faris M; Yahyaoui M; Chkili T
Rev Med Interne; 2002 May; 23(5):419-31. PubMed ID: 12064213
[TBL] [Abstract][Full Text] [Related]
13. Effects of long-term treatment in Wilson's disease with D-penicillamine and zinc sulphate.
Czlonkowska A; Gajda J; Rodo M
J Neurol; 1996 Mar; 243(3):269-73. PubMed ID: 8936358
[TBL] [Abstract][Full Text] [Related]
14. A clinical study of Wilson's disease: The experience of a single Egyptian Paediatric Hepatology Unit.
El-Karaksy H; Fahmy M; El-Raziky MS; El-Hawary M; El-Sayed R; El-Koofy N; El-Mougy F; El-Hennawy A; El-Shabrawi M
Arab J Gastroenterol; 2011 Sep; 12(3):125-30. PubMed ID: 22055589
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of Wilson's disease with penicillamine and zinc salts: a follow-up study].
Li M; Zhang YH; Qin J
Zhonghua Er Ke Za Zhi; 2003 Feb; 41(2):119-22. PubMed ID: 14759316
[TBL] [Abstract][Full Text] [Related]
16. Effect of penicillamine and zinc on iron metabolism in Wilson's disease.
Medici V; Di Leo V; Lamboglia F; Bowlus CL; Tseng SC; D'Incà R; Irato P; Burra P; Martines D; Sturniolo GC
Scand J Gastroenterol; 2007 Dec; 42(12):1495-500. PubMed ID: 17994470
[TBL] [Abstract][Full Text] [Related]
17. Results of treatment of Wilson's disease--own observations.
Jabłońska-Kaszewska I; Drobińska-Jurowiecka A; Dabrowska E; Trocha H
Med Sci Monit; 2003 Aug; 9 Suppl 3():9-14. PubMed ID: 15156603
[TBL] [Abstract][Full Text] [Related]
18. Zinc therapy increases duodenal concentrations of metallothionein and iron in Wilson's disease patients.
Sturniolo GC; Mestriner C; Irato P; Albergoni V; Longo G; D'Incà R
Am J Gastroenterol; 1999 Feb; 94(2):334-8. PubMed ID: 10022625
[TBL] [Abstract][Full Text] [Related]
19. Histologic evolution and long-term outcome of Wilson's disease: results of a single-center experience.
Sini M; Sorbello O; Sanna F; Battolu F; Civolani A; Fanni D; Faa G; Demelia L
Eur J Gastroenterol Hepatol; 2013 Jan; 25(1):111-7. PubMed ID: 23011036
[TBL] [Abstract][Full Text] [Related]
20. Clinical presentation and treatment of Wilson's disease: a single-centre experience.
Pellecchia MT; Criscuolo C; Longo K; Campanella G; Filla A; Barone P
Eur Neurol; 2003; 50(1):48-52. PubMed ID: 12824712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
